Global Antivenoms for Treating Spider Bites Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antivenoms for Treating Spider Bites Market Research Report 2024
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
According to Mr Accuracy reports’s new survey, global Antivenoms for Treating Spider Bites market is projected to reach US$ 194.5 million in 2029, increasing from US$ 144 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antivenoms for Treating Spider Bites market research.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antivenoms for Treating Spider Bites market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL
Pfizer
Merck
BTG
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Hospitals
Clinic
Non-profit Institutions
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antivenoms for Treating Spider Bites report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Antivenoms for Treating Spider Bites market is projected to reach US$ 194.5 million in 2029, increasing from US$ 144 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antivenoms for Treating Spider Bites market research.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antivenoms for Treating Spider Bites market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL
Pfizer
Merck
BTG
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segment by Application
Hospitals
Clinic
Non-profit Institutions
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antivenoms for Treating Spider Bites report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices